


Supplem Table 1. Immunoprofile and Molecular Findings of rare BCOR variant fusions *KMT2D-BCOR* and *BCOR-CHD9* in undifferentiated round and spindle cell sarcomas.

Age/Sex	Site	Fusion genes (exon)*	<i>BCOR</i> FISH	<i>NTRK3</i> mRNA up- regulation	Immunohistochemistry				
					Pan-Trk	<i>BCOR</i>	<i>NTRK1</i>	H3K27me3	TLE1
38/M	scapula	<i>KMT2D</i> (39)- <i>BCOR</i> (6) <i>BCOR</i> (4)- <i>KMT2D</i> (22)	–	+	+ (95%, strong)	+	–	Loss	+
10/F	pelvic	<i>KMT2D</i> (42)- <i>BCOR</i> (4) <i>BCOR</i> (1)- <i>KMT2D</i> (29)	–	+	+ (60%, moderate)	+	–	NA	+
41/F	kidney	<i>BCOR</i> (1)- <i>CHD9</i> (2) <i>CHD9</i> (2)- <i>BCOR</i> (4)	+	+	+ (100%, strong)	–	–	Loss	NA


*The most abundant exon compositions are shown for fusion transcripts with multiple different fusion junctions. NA, not available.

Supplementary Figure 1. No *NTRK1* (A-B) or *NTRK2* (C-D) up-regulation was observed in BCOR family tumors in both platforms (A&C, whole transcriptome sequencing; B&D, targeted RNA sequencing) (expression levels in RPKM).


A




B



C



D



Supplementary Figure 2. Solitary fibrous tumors showed diffuse and strong NTRK1 immunoreactivity.

